{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.28","value":"-8.3"},{"groupId":"OG001","spread":"5.84","value":"-9.2"},{"groupId":"OG002","spread":"7.55","value":"-10.5"},{"groupId":"OG003","spread":"7.82","value":"-12.1"},{"groupId":"OG004","spread":"5.67","value":"-11.7"}]}],"title":"Course 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.56","value":"-8.0"},{"groupId":"OG001","spread":"2.92","value":"-7.1"},{"groupId":"OG002","spread":"5.42","value":"-8.9"},{"groupId":"OG003","spread":"3.24","value":"-8.6"},{"groupId":"OG004","spread":"5.47","value":"-7.5"}]}],"title":"Course 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"18"}],"units":"Participants"}],"description":"Mean maximum % long interspread nuclear element-1 (LINE-1) demethylation decrease from baseline after oral decitabine + cedazuridine (E7727) or ASTX727 compared with IV decitabine 20 mg/m\\^2 in the dose escalation stage.","dispersionType":"Standard Deviation","groups":[{"description":"Cohort 1 was administered 40 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m\\^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).","id":"OG000","title":"Phase 1 Dose Escalation Cohort 1"},{"description":"Cohort 2 was administered 60 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m\\^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).","id":"OG001","title":"Phase 1 Dose Escalation Cohort 2"},{"description":"Cohort 3 was administered 100 mg oral cedazuridine and 20 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m\\^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).","id":"OG002","title":"Phase 1 Dose Escalation Cohort 3"},{"description":"Cohort 4 was administered 100 mg oral cedazuridine and 40 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m\\^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).","id":"OG003","title":"Phase 1 Dose Escalation Cohort 4"},{"description":"Cohort 5 was administered 100 mg oral cedazuridine and 30 mg oral decitabine. Participants were enrolled into successive cohorts in which either the cedazuridine or decitabine oral dose was varied in Course 1 Day 2 through Course 1 Day 5 for comparison with a single dose of IV decitabine at 20 mg/m\\^2 administered on Day 1 by continuous IV infusion over 1 hour (28 days per course).","id":"OG004","title":"Phase 1 Dose Escalation Cohort 5"}],"paramType":"MEAN","populationDescription":"The pharmacodynamic population includes all participants in Phase 1 with evaluable data who received at least one dose of investigational product.","reportingStatus":"POSTED","timeFrame":"Pre-dose to Day 28 in Course 2 (28 days per course)","title":"Mean Maximum %LINE Demethylation in Phase 1","type":"SECONDARY","unitOfMeasure":"Percent change"}